Passage Bio Inc (NAS:PASG)
$ 0.657 -0.0029 (-0.44%) Market Cap: 40.58 Mil Enterprise Value: -18.43 Mil PE Ratio: 0 PB Ratio: 0.56 GF Score: 36/100

Passage Bio Inc at Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Days (Virtual) Transcript

Apr 03, 2023 / 07:55PM GMT
Release Date Price: $1.19 (+24.26%)
Ry Forseth
Guggenheim Partners - Moderator

Well, good afternoon, everyone, and welcome again to the 5th Annual Guggenheim Genomic Medicines and Rare Disease Conference. My name is Ry Forseth. And here, we have William Chou, part of Passage Bio. He's the Chief Executive Officer, and he's going to give us an overview of the company. Thank you so much for joining us today.

William Chou
Passage Bio, Inc. - President and CEO

Thanks for having me.

Ry Forseth
Guggenheim Partners - Moderator

Let's start with a platform review and key updates we can expect for 2023.

William Chou
Passage Bio, Inc. - President and CEO

Sure. So I'll start out with our GM1 program for GM1 gangliosidosis. So we've treated six -- we've treated eight patients and shared data from the first six. And what we've seen from the first six patients is product has a favorable toxicity profile. We saw no SAEs due to the product. Second is we saw a good biologic response in all the patients treated, and we

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot